NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Jonathan C. Javitt Purchases 40,000 Shares of Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Jonathan C. Javitt bought 40,000 shares of the business’s stock in a transaction on Tuesday, December 17th. The stock was acquired at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the acquisition, the chairman now directly owns 84,634 shares of the company’s stock, valued at $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP opened at $1.55 on Thursday. The stock has a market cap of $18.69 million, a price-to-earnings ratio of -0.72 and a beta of 1.25. NRx Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $7.33. The business has a fifty day moving average of $1.28 and a 200-day moving average of $1.88.

Hedge Funds Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned approximately 0.14% of NRx Pharmaceuticals at the end of the most recent reporting period. 4.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NRXP shares. Ascendiant Capital Markets boosted their price objective on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.